Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  OpGen, Inc.    OPGN

OPGEN, INC.

(OPGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

OPGEN INC : Completion of Acquisition or Disposition of Assets, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)

04/02/2020 | 05:32pm EST

Item 2.01 Completion of Acquisition or Disposition of Assets.

On April 1, 2020 (the "Closing Date"), OpGen, Inc. (the "Company") completed its business combination transaction (the "Transaction") with Curetis N.V., a public company with limited liability under the laws of the Netherlands (the "Seller"), as contemplated by the Implementation Agreement, dated as of September 4, 2019 (the "Implementation Agreement"), by and among the Company, the Seller, and Crystal GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany and wholly owned subsidiary of the Company ("Purchaser"). Pursuant to the Implementation Agreement, the Purchaser acquired all of the shares of Curetis GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany ("Curetis GmbH") and certain other assets and liabilities of the Seller, as further described below, and paid, as the sole consideration, 2,028,208 shares of the Company's common stock, par value $0.01 per share (the "Common Stock"), to the Seller, and reserved for future issuance (a) 134,356 shares of Common Stock, in connection with its assumption of the Seller's 2016 Stock Option Plan, as amended (the "Seller Stock Option Plan"), and the outstanding awards thereunder, and (b) 500,000 shares of Common Stock to be issued upon the conversion, if any, of certain convertible notes issued by the Seller. The 2,028,208 shares of Common Stock issued to the Seller represents approximately 13.8% of the outstanding Common Stock of the Company as of the date thereof.

At the closing, the Company assumed all of the liabilities of the Seller solely and exclusively related to the acquired business, which is providing innovative solutions, through development of proprietary platforms, diagnostic content, applied bioinformatics, lab services, research services and commercial collaborations and agreements, for molecular microbiology, diagnostics designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patient (the "Curetis Business"). Pursuant to the Implementation Agreement, the Company also assumed and adopted the Seller Stock Option Plan as an Amended and Restated Stock Option Plan of the Company. In connection with the foregoing, the Company assumed all awards thereunder that were outstanding as of the Closing Date and converted such awards into options to purchase shares of Common Stock pursuant to the terms of the applicable award. In addition, the Company assumed, at the closing, all of the outstanding convertible notes issued by Seller in favor of YA II PN, LTD, pursuant to the previously disclosed Assignment of the Agreement for the Issuance of and Subscription to Notes Convertible into Shares, dated February 24, 2020 (the "Assignment Agreement"), and entered into pursuant to the Implementation Agreement.

The foregoing summary of certain terms of the Implementation Agreement, the Amended and Restated Stock Option Plan, and the Assignment Agreement do not purport to be complete and are subject to, and qualified in their entirety by, the full text of such documents. The Implementation Agreement and the Assignment Agreement are incorporated by reference as Exhibits 2.1 and 10.2 to this Current Report on Form 8-K, and the Amended and Restated Stock Option Plan is attached to this Current Report on Form 8-K as Exhibit 10.1, each of such exhibits are incorporated herein by reference.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Certain Directors and Officers

Effective upon the consummation of the Transaction, and pursuant to the terms of the Implementation Agreement, (a) Evan Jones resigned from his positions as the Company's Chief Executive Officer ("CEO") and Chairman of the Board of Directors of the Company (the "Board"), and (b) Tina Nova, Ph.D. and Misti Ushio, Ph.D. resigned from their position as members of the Board. Mr. Jones remains as a director of the Company, as does Don Elsey, the chair of the Audit Committee of the Board.

Mr. Jones' resignation as CEO of the Company, effective April 1, 2020, was a resignation for "Good Reason" as defined in his Executive Change in Control and Severance Benefits Agreement, dated September 24, 2018 (the "Severance Agreement"). The Severance Agreement is incorporated by reference as Exhibit 10.3 to this Current Report on Form 8-K. Under the Severance Agreement, Mr. Jones will receive, as severance, an amount equal to one-twelfth of his annual base salary for six months. In addition, the Company and Mr. Jones entered into a Transition Agreement and General Release (the "Transition Agreement"), pursuant to which Mr. Jones will provide transition and integration assistance services to the Company. Mr. Jones will receive a consulting fee of approximately $23,000 per month in exchange for the services being provided under the Transition Agreement. Finally, if Mr. Jones continues to provide services to the Company until October 1, 2020 he will be paid his accrued but unpaid 2018 incentive bonus of $75,000. Mr. Jones has provided a general release of claims against the Company in the Transition Agreement as required by the Severance Agreement.

The foregoing summary of the Transition Agreement is not complete and is qualified in its entirety by reference to the Transition Agreement, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10.4 and incorporated herein by reference.

Board of Directors

In connection with the closing of the Transaction and pursuant to the Implementation Agreement, effective as of April 1, 2020, Mario Crovetto, Prabhavathi Fernandes, Ph.D., William E. Rhodes, III, and Oliver Schacht, Ph.D. were appointed to the Board, in addition to Mr. Jones and R. Donald Elsey, who are remaining on the Board. Mr. Rhodes will serve as the non-executive Chairman of the Board. None of Mr. Crovetto, Dr. Fernandes, or Mr. Rhodes are a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. The Board has determined that each of Mr. Rhodes, Dr. Fernandes, Mr. Crovetto and Mr. Elsey are independent under the applicable standards of the Securities and Exchange Commission ("SEC") and Nasdaq. Neither of Mr. Jones or Mr. Schacht is an independent member of the Board.

The Company will enter into its standard form of Indemnification Agreement with each of Mr. Schacht, Mr. Crovetto, Dr. Fernandes and Mr. Rhodes, which provides for indemnification of the indemnitee to the fullest extent allowed by Delaware law. The form of Indemnification Agreement is incorporated by reference as Exhibit 10.5 to this Current Report on Form 8-K.

The biographies of the newly appointed independent directors are set forth below. See below for the biography of Mr. Schacht.

· Mr. Crovetto served as the chairman of the Audit Committee of Curetis N.V.

   since its initial public offering ("IPO") in 2015 until April 1, 2020. Mr.
   Crovetto has been working as an independent advisor on M&A and corporate
   projects, notably integrations, divestments and financings since 2011. From
   1999 to 2011, he was the Chief Financial Officer ("CFO") of Eurand NV
   (Specialty Pharmaceuticals), which he took public to Nasdaq in 2007. From 1990
   to 1999, he held various senior business positions at Recordati
   (Pharmaceuticals), including VP of Corporate Development, Division Manager of
   Diagnostics and Chief Financial Officer. Prior to that, he held various
   positions at Montedison (Specialty Chemicals), Digital Equipment Corporation,
   Mobil and SIAR (Management Consulting). Mr. Crovetto holds a BSc in Economics
   from the Università Cattolica del Sacro Cuore, Milan and a Master's degree in
   Business Economics from Harvard University, Cambridge, MA.

· Dr. Fernandes served as a member of the Curetis N.V. Supervisory Board from

   2016 until April 1, 2020. Until her retirement in December 2016, she was
   President and CEO and a member of the board of directors of Cempra
   Pharmaceuticals, a company she founded. In 2012, she led the IPO and listing on
   Nasdaq for Cempra. Her career of more than four decades has focused on
   anti-infectives, first on clinical microbiology and infectious diseases and
   subsequently on pharmaceutical discovery and development. Prior to Cempra, Dr.
   Fernandes held executive leadership positions at pharmaceutical corporations
   including Bristol-Myers Squibb Pharmaceutical Research Institute, Abbott
   Laboratories and The Squibb Institute for Medical Research. She serves on the
   editorial board of several journals and she has authored numerous publications
   and numerous reviews and book chapters and serves as an advisor to three U.S.
   based biotechnology companies. In 2017, she was appointed to the National
   Biodefense Science Board (NBSB) in the Health and Human Services department of
   the U.S. government and in 2018 she was appointed its Chairperson. In 2018, she
   was appointed to the Scientific Advisory Board of Global Antibiotic Research &
   Development Partnership (GARDP), a joint initiative of DNDi and the WHO, which
   aims to develop and deliver new treatments for bacterial infections, and made
   Chair of it in November 2019. Finally, Dr. Fernandes joined the Aelin
   Therapeutics Board in Leven, Belgium, a company founded on protein aggregation
   technology that discovers and develops oncology and antibiotic products. Dr.
   Fernandes obtained her MSc in India, and did a Ph.D. and post-doctoral
   fellowship in bacterial cell membranes and clinical and public health
   microbiology.

· Mr. Rhodes served as the chairman of the Supervisory Board of Curetis N.V.

since its IPO in 2015 until April 1, 2020. Mr. Rhodes is a healthcare executive

with more than 30 years of experience in the healthcare industry. During his

14-year career at Becton, Dickinson and Company (BD, 1998-2012), Mr. Rhodes

held several senior leadership positions, including roles as Worldwide

President of BD Biosciences (2009-2011), a greater than $1 billion revenue

segment of BD. He was also an Executive Officer of BD, and was responsible for

corporate strategy and merger and acquisition functions for all of BD's

businesses. Furthermore, he founded BD Ventures, the venture capital arm of

Becton, Dickinson and Co. Prior to Becton Dickinson, he served in senior

business development positions at Johnson & Johnson and Pfizer Inc. Mr. Rhodes

also served as president at The William-James Co. and has a track record of

over 20 successful acquisitions and divestitures. He was director of Andor

Technologies plc (2013-2014), and has served on the boards of Novocell Inc.,

Conticare Medical, Vitagen Inc., Cellector Inc. and the California Healthcare

Institute, BIO, the San Jose State University Research Foundation and Silicon

Valley Leadership Group. He currently serves as director of Third Day Advisors

LLC (since 2013), Omega Group plc (since 2013), Paramit Corporation LLC (since

2014), and as a member of the Advisory Board of Cayuga Venture Fund (since

2013). Mr. Rhodes has a number of advisory roles with Cornell University,

including serving on the Advisory Councils of the McGovern Family Center for

Life Sciences (since 2013) and Entrepreneurship at Cornell (since 2015). He

also was appointed to the Cornell College of Agriculture and Life Sciences

Dean's Council (2016) and served as a Venture Consultant for Cornell's

Blackstone Launchpad (2016). Moreover, he is on the Editorial Board of the

journal Clinical and Translational Medicine. Mr. Rhodes holds a Master's degree

in International Business from Seton Hall University and a BSc degree from

Cornell University. He originated eleven U.S. patents for novel topical drugs

and has been a lecturer on entrepreneurship in life sciences, innovation . . .

Item 8.01 Other Information.

On April 1, 2020, the Company issued a press release announcing the closing of the Transaction, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The required financial statements and pro forma financial information related to the acquisition of the Curetis Business are not filed with this Current Report on Form 8-K. OpGen, Inc. will file the required financial statements and pro forma financial information related to the Curetis Business acquisition within the 75-day time period required by the applicable SEC regulations.

The following exhibits are filed or furnished herewith:


Exhibit No. Document
2.1                Implementation Agreement, dated as of September 4, 2019, by and among
                 Curetis N.V., as Seller, and Crystal GmbH, as Purchaser and OpGen, Inc.
                 (incorporated by reference to the Company's Current Report on Form 8-K
                 filed with the SEC on September 4, 2019)
10.1 *!            Amended and Restated Stock Option Plan
10.2               Assignment of the Agreement for the Issuance of and Subscription to
                 Notes Convertible into Shares, dated February 24, 2020, among OpGen, Inc.,
                 YA II PN, LTD, and Curetis N.V. (incorporated by reference to the
                 Company's Current Report on Form 8-K filed with the SEC on February 28,
                 2020)
10.3 !             Executive Change In Control and Severance Benefits Agreement, dated
                 September 24, 2018 between OpGen, Inc. and Evan Jones (incorporated by
                 reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K,
                 filed on September 25, 2018)
10.4 *!            Transition Agreement between OpGen, Inc. and Evan Jones
10.5               Form of Indemnification Agreement (incorporated by reference to the
                 Company's Registration Statement on Form S-1 filed with the SEC on March
                 3, 2015)
10.6 *!            Amended and Restated Management Services Agreement, dated April 2, 2020,
                 by and between OpGen, Inc. and Oliver Schacht
99.1 *             Press Release issued by OpGen, Inc. dated April 1, 2020





* Filed herewith.
! Management or compensatory agreement.

© Edgar Online, source Glimpses

All news about OPGEN, INC.
12/01OPGEN : Corporate Presentation (PDF)
PU
12/01OpGen Group Company Ares Genetics Advances ares-genetics.cloud Platform, Pres..
GL
11/24OPGEN INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equ..
AQ
11/24OPGEN : Announces $10 Million Private Placement Priced at the Market
AQ
11/24OpGen, Inc. Announces $10 Million Private Placement Priced at the Market
GL
11/16OPGEN : Note 2 - Liquidity and management's plans
AQ
11/13OPGEN : Corporate Presentation (PDF)
PU
11/13OPGEN INC : Entry into a Material Definitive Agreement, Other Events, Financial ..
AQ
11/12OPGEN : Ares Genetics Commercially Launches NGS-based Antibiotic Resistance Test..
AQ
11/12OpGen Group Company Ares Genetics Commercially Launches NGS-based Antibiotic ..
GL
More news
Financials (USD)
Sales 2020 4,12 M - -
Net income 2020 -26,4 M - -
Net Debt 2020 14,6 M - -
P/E ratio 2020 -1,17x
Yield 2020 -
Capitalization 44,8 M 44,8 M -
EV / Sales 2020 14,4x
EV / Sales 2021 7,40x
Nbr of Employees 39
Free-Float 99,9%
Chart OPGEN, INC.
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 5,33 $
Last Close Price 1,99 $
Spread / Highest target 184%
Spread / Average Target 168%
Spread / Lowest Target 151%
EPS Revisions
Managers
NameTitle
Oliver Schacht Chief Executive Officer & Director
Bill E. Rhodes Non-Executive Chairman
Johannes Bacher Chief Operating Officer
Timothy C. Dec CFO, Secretary & Chief Accounting Officer
Vadim Sapiro Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
OPGEN, INC.76.11%45
MODERNA, INC.631.08%56 587
LONZA GROUP AG56.34%45 782
CELLTRION, INC.91.71%42 101
IQVIA HOLDINGS INC.10.05%32 601
SEAGEN INC.54.94%31 921